Mink Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
INKT Nasdaq 8731 https://www.minktherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mink Therapeutics Inc

This MiNK Therapeutics Insider Increased Their Holding In The Last Year - Apr 11th, 2024 12:05 pm
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR - Apr 8th, 2024 4:00 pm
All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy - Mar 25th, 2024 4:00 pm
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript - Mar 22nd, 2024 5:25 pm
Q4 2023 Mink Therapeutics Inc Earnings Call - Mar 22nd, 2024 3:06 am
MiNK Reports Fourth Quarter and Year-End 2023 Results - Mar 21st, 2024 11:00 am
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report - Mar 7th, 2024 12:30 pm
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 - Mar 6th, 2024 1:30 pm
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab - Feb 14th, 2024 1:00 pm
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications - Feb 6th, 2024 1:00 pm
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene - Jan 30th, 2024 1:00 pm
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development - Dec 20th, 2023 12:30 pm
MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges - Nov 9th, 2023 1:05 pm
MiNK Therapeutics Reports Third Quarter 2023 Results - Nov 9th, 2023 12:00 pm
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023 - Nov 3rd, 2023 4:00 pm
MiNK Therapeutics Insider Ups Holding During Year - Nov 3rd, 2023 11:41 am
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update - Oct 30th, 2023 12:00 pm
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023 - Sep 27th, 2023 1:05 pm
Can MiNK Therapeutics (NASDAQ:INKT) Afford To Invest In Growth? - Sep 23rd, 2023 12:37 pm
MiNK Therapeutics to Participate in September Investor Conferences - Aug 24th, 2023 12:30 pm